Vertex Pharmaceuticals recently presented updated interim data at the 2025 ASN Kidney Week, revealing significant proteinuria ...
StockStory.org on MSN
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call
Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively ...
The company posted revenue of $192.1 million in the period, which beat Street forecasts. Five analysts surveyed by Zacks expected $191.5 million. For the current quarter ending in December, Vertex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback